文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

作者信息

Singh Jasvinder A, Furst Daniel E, Bharat Aseem, Curtis Jeffrey R, Kavanaugh Arthur F, Kremer Joel M, Moreland Larry W, O'Dell James, Winthrop Kevin L, Beukelman Timothy, Bridges S Louis, Chatham W Winn, Paulus Harold E, Suarez-Almazor Maria, Bombardier Claire, Dougados Maxime, Khanna Dinesh, King Charles M, Leong Amye L, Matteson Eric L, Schousboe John T, Moynihan Eileen, Kolba Karen S, Jain Archana, Volkmann Elizabeth R, Agrawal Harsh, Bae Sangmee, Mudano Amy S, Patkar Nivedita M, Saag Kenneth G

机构信息

University of Alabama at Birmingham.510 20th Street South, Birmingham, AL 35294, USA.

出版信息

Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641.

DOI:10.1002/acr.21641
PMID:22473917
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4081542/
Abstract
摘要

相似文献

[1]
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Arthritis Care Res (Hoboken). 2012-5

[2]
The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road.

Arthritis Rheum. 2008-6-15

[3]
Level of the indication of biologic agents in the 2012 American College of Rheumatology recommendations for the treatment of rheumatoid arthritis: comment on the article by Singh et al.

Arthritis Care Res (Hoboken). 2013-5

[4]
Oral glucocorticoids should be included in any recommendation for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: comment on the article by Singh et al.

Arthritis Care Res (Hoboken). 2012-10

[5]
American College of Rheumatology treatment guidelines continue to omit guidance on glucocorticoids: comment on the article by Singh et al.

Arthritis Care Res (Hoboken). 2012-10

[6]
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Arthritis Rheum. 2008-6-15

[7]
Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road.

Arthritis Care Res (Hoboken). 2012-5

[8]
Reply: To PMID 22473917.

Arthritis Care Res (Hoboken). 2013-5

[9]
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.

Arthritis Rheumatol. 2017-6-16

[10]
Current therapeutic agents and treatment paradigms for the management of rheumatoid arthritis.

Am J Manag Care. 2014-5

引用本文的文献

[1]
A Review of the Current Clinical Aspects of Sjögren's Disease: Geographical Difference, Classification/Diagnostic Criteria, Recent Advancements in Diagnostic Methods, and Molecular Targeted Therapy.

J Clin Med. 2025-8-7

[2]
Pharmacogenomics of TNF inhibitors.

Front Immunol. 2025-5-21

[3]
Cancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish register-based cohort study.

RMD Open. 2025-4-20

[4]
Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment.

Front Med (Lausanne). 2025-3-28

[5]
Management of IgG4-related cholangitis: diagnosis, therapy, and long-term surveillance.

Gastroenterol Rep (Oxf). 2025-4-4

[6]
Detection of substantial numbers of latent tuberculosis and positive hepatitis B serology results in rheumatology patients preparing to receive intensified immunosuppressive therapy in a low-prevalence country: why screening still matters.

Clin Rheumatol. 2025-4

[7]
The pattern of anti-IL-6 versus non-anti-IL-6 biologic disease modifying anti-rheumatic drugs use in patients with rheumatoid arthritis in Wales, UK: a real-world study using electronic health records.

Rheumatol Adv Pract. 2024-12-14

[8]
Tofacitinib Safety and Effectiveness in Canadian Patients with Rheumatoid Arthritis by Cardiovascular Risk Enrichment: Subanalysis of the CANTORAL Study.

Rheumatol Ther. 2024-12

[9]
Application of disease activity index in rheumatoid arthritis management in Korea.

J Rheum Dis. 2024-10-1

[10]
Tuberculosis screening for patients on biologic Medications: A Single-Center experience and Society guideline Review, Monroe County, New York, 2018-2021.

J Clin Tuberc Other Mycobact Dis. 2024-6-22

本文引用的文献

[1]
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Cochrane Database Syst Rev. 2011-2-16

[2]
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

Arthritis Rheum. 2011-3

[3]
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Arthritis Rheum. 2010-9

[4]
Tocilizumab for rheumatoid arthritis.

Cochrane Database Syst Rev. 2010-7-7

[5]
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Ann Rheum Dis. 2010-5-5

[6]
Golimumab for rheumatoid arthritis.

Cochrane Database Syst Rev. 2010-1-20

[7]
Biologics for rheumatoid arthritis: an overview of Cochrane reviews.

Cochrane Database Syst Rev. 2009-10-7

[8]
Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.

Ann Rheum Dis. 2009-7

[9]
Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.

Arthritis Rheum. 2008-10-15

[10]
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.

Lancet. 2008-8-2

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索